Drugs / NGGT001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06302608 | Feb 2023 → May 2024 overdue | Bietti crystalline corneoretinal dystrophy | Xiamen Ophthalmology Center Affiliated to Xiamen University | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06706427 | Mar 2024 → Nov 2025 overdue | Bietti crystalline corneoretinal dystrophy | NGGT (Suzhou) Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGGT001 | “Biological: NGGT001” NCT06706427 ↗ |
| Known as | rAAV-hCYP4V2 | “AAV encoding CYP4V2 (rAAV-hCYP4V2, NGGT001 [Next Generation Gene Therapeutics]).” PMID 39786763 ↗ Feb 2025 |
| Modality | Gene therapy (AAV / viral vector) | “gene therapy with adeno-associated virus (AAV) encoding CYP4V2” PMID 39786763 ↗ Feb 2025 |
| Route | Other | “subretinal injections” PMID 39786763 ↗ Feb 2025 |
| Target | CYP4V2 | “AAV encoding CYP4V2” PMID 39786763 ↗ Feb 2025 |